SPOTLIGHT -
EP. 1: Follicular Lymphoma; Triggers to Initiate Therapy
EP. 2: Follicular Lymphoma: Consolidation and Maintenance
EP. 3: Sequencing Therapies for Follicular Lymphoma
EP. 4: R2-CHOP for Relapsed Follicular Lymphoma
EP. 5: Emerging Therapies for Follicular Lymphoma
EP. 6: Chronic Lymphocytic Leukemia; Initiating Therapy
EP. 7: CLL Risk Stratification and Treatment Approach
EP. 8: The Role of Maintenance Therapy in CLL
EP. 9: Sequencing Therapies for Relapsed/Refractory CLL
EP. 10: Managing Ibrutinib Toxicity in CLL
EP. 11: Ibrutinib for CLL with Deletion 17p
EP. 12: CAR-T Cell Therapies in CLL
EP. 13: Risk-Based Therapy for DLBCL
EP. 14: Treating High-Grade Lymphoma
EP. 15: Maintenance Therapy for DLBCL
EP. 16: Relapsed/Refractory DLBCL
EP. 17: CAR-T Therapy for DLBCL
EP. 18: DLBCL: CAR-T as Curative Treatment/Bridge to Transplant
EP. 19: The Future of Treatment of B-Cell Lymphoma
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
